Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention (PREDIRCAM 2)
Primary Purpose
Obesity Type I and II
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Telemedic assistance with a technological system
Standard care
Sponsored by

About this trial
This is an interventional treatment trial for Obesity Type I and II
Eligibility Criteria
Inclusion Criteria:
Preclinical Phase:
1. People over 18 years with or without obesity and with ability for technology management
Clinical Phase:
- People between 18 and 65 years.
Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2:
- Grade I or II without sleep apnea syndrome and ischemic heart disease
- Absence of metabolic processes (dyslipidemia) or associated hypertension requiring drug treatment at the time of inclusion in the study.
- People with ability for technology management
Exclusion Criteria:
Preclinical Phase:
1. Serious illness and / or disabling
Clinical Phase:
- Diabetes defining according to American Diabetes Association (ADA) criteria.
- Subjects with moderate to severe active disease at the time of inclusion in the study protocol
- Impaired glucose metabolism related diseases associated with diabetes mellitus or drugs interfering carbohydrate metabolism.
- Cardiovascular disease
- Dyslipidemia or hypertension requiring drug treatment.
- Alcohol consumption
- Pregnancy
- Serious illness and / or disabling
Sites / Locations
- Hospital de la Santa Creu i Sant Pau
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Conventional assistance
Telemedic assistance
Arm Description
Usual treatment of obesity in terms of monitoring lifestyle habits
telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
Outcomes
Primary Outcome Measures
Weight loss
Secondary Outcome Measures
Cardiometabolic risk prevention
We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study
Full Information
NCT ID
NCT01919372
First Posted
August 7, 2013
Last Updated
March 6, 2018
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Grupo de Bioingenieria y Telemedicina -ETSI Telecomunicacion. Universidad Politecnica de Madrid, Spanish Clinical Research Network - SCReN
1. Study Identification
Unique Protocol Identification Number
NCT01919372
Brief Title
Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention
Acronym
PREDIRCAM 2
Official Title
Intensificación y monitorización telemática Personalizada de la modificación Del Estilo de Vida en el Tratamiento de la Obesidad y la prevención Del Riesgo cardiometabólico
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
October 29, 2015 (Actual)
Primary Completion Date
December 30, 2017 (Actual)
Study Completion Date
January 25, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Grupo de Bioingenieria y Telemedicina -ETSI Telecomunicacion. Universidad Politecnica de Madrid, Spanish Clinical Research Network - SCReN
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This project is based on the contribution that could offer a technological system for a continuous monitoring, individualized treatment of obesity and prevention of cardiometabolic complications in high risk population.
The main objective of PREDIRCAM study is to evaluate the benefits obtained with the use in high cardiometabolic risk individuals of a telemedical platform integrating applications for monitoring and providing recommendations to improve lifestyle habits (diet and physical activity) in a healthier way.
The study population are obese subjects (type I or II) aged between 25 and 65 years with a 12 month follow-up. In this population it will be analysed the cost-effectiveness of a telemedic assistance with a technological system and its ability to modify lifestyle habits, reduce weight and cardiovascular risk associated parameters.
Previously to the clinical implementation, a pilot study for testing the telemedical system will be made. Efficacy and security variables will be evaluated along the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity Type I and II
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
183 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Conventional assistance
Arm Type
Active Comparator
Arm Description
Usual treatment of obesity in terms of monitoring lifestyle habits
Arm Title
Telemedic assistance
Arm Type
Experimental
Arm Description
telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
Intervention Type
Device
Intervention Name(s)
Telemedic assistance with a technological system
Other Intervention Name(s)
PREDIRCAM
Intervention Type
Other
Intervention Name(s)
Standard care
Primary Outcome Measure Information:
Title
Weight loss
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Cardiometabolic risk prevention
Description
We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Preclinical Phase:
1. People over 18 years with or without obesity and with ability for technology management
Clinical Phase:
People between 18 and 65 years.
Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2:
Grade I or II without sleep apnea syndrome and ischemic heart disease
Absence of metabolic processes (dyslipidemia) or associated hypertension requiring drug treatment at the time of inclusion in the study.
People with ability for technology management
Exclusion Criteria:
Preclinical Phase:
1. Serious illness and / or disabling
Clinical Phase:
Diabetes defining according to American Diabetes Association (ADA) criteria.
Subjects with moderate to severe active disease at the time of inclusion in the study protocol
Impaired glucose metabolism related diseases associated with diabetes mellitus or drugs interfering carbohydrate metabolism.
Cardiovascular disease
Dyslipidemia or hypertension requiring drug treatment.
Alcohol consumption
Pregnancy
Serious illness and / or disabling
Facility Information:
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
12. IPD Sharing Statement
Learn more about this trial
Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention
We'll reach out to this number within 24 hrs